We can have a lot of fun with revenue projections,

We can have a lot of fun with revenue projections, but what excites me most is ScripsAmerica now has three solid revenue streams. Number one is Compounding Pharmacy. Compound Pharmacy is not facing anything unusual right now. My 37 years in the industry allows me to say with confidence all pharma companies deal with the same deductible issue patients face at the beginning of the year. Compound Pharmacy will as strong as ever by March. The reason is because patients need and want this therapy and secondly physicians have more confidence in compounding than they do in oral medications. Next SCRC now has PIMD growing and producing revenues each month, the potential with PIMD will add significantly to the bottom line as we progress throughout the year. Third SCRC has the new diabetes patient supply program which I believe will grow significantly each month as well. Mr. Schneiderman has developed a business model which is flourishing. By the end of the year we won't recognize this company. How about RapiMeds? As far as I am concerned, as long as Mr. Schneiderman maintains his excitement and belief in this product, so will I. When RapiMeds joins the SCRC bottom line, I agree it will cause a "buying frenzy". Revenues, Bank Financing, Cash in the Bank, and a CEO who is driven to success, SCRC is solid and is in good hands.